Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesDevelopment of semagacestat (LY450139), a functional gamma-secretase inhibitor, for the treatment of Alzheimer's disease
Expert Opinion in Pharmacotherapy, 06/19/09
Henley DB et al. - Semagacestat seems to be well tolerated, with most adverse events related to its actions on inhibition of peripheral Notch cleavage. Thus far, clinical efficacy has not been detectable because of the short duration of the current trials. Phase III trials with 21 months of active treatment are currently underway.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
Investigational New Drugs, 12/17/09
Milatuzumab – a promising new immunotherapeutic agent
Expert Opinion on Investigational Drugs, 12/17/09
Association of trial registration with the results and conclusions of published trials of new oncology drugs
Trials, 12/17/09
Today in Neuro/Psych pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Modafinil for multiple sclerosis fatigue: Does it work?
Clinical Neurology and Neurosurgery, 12/17/09
Oxaliplatin-induced Lhermitte's phenomenon as a manifestation of severe generalized neurotoxicity
Oncology (Karger), 12/17/09
Sponsor
Article Search
Sponsor
Sponsor